- Home
- EDIT vs CATX Comparison
EDIT vs CATX Comparison
Compare EDIT & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- CATX
- Stock Information
- Founded
- EDIT 2013
- CATX 1983
- Country
- EDIT United States
- CATX United States
- Employees
- EDIT N/A
- CATX N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- CATX Medical/Dental Instruments
- Sector
- EDIT Health Care
- CATX Health Care
- Exchange
- EDIT Nasdaq
- CATX Nasdaq
- Market Cap
- EDIT 263.7M
- CATX 239.0M
- IPO Year
- EDIT 2016
- CATX N/A
- Fundamental
- Price
- EDIT $2.57
- CATX $3.35
- Analyst Decision
- EDIT Buy
- CATX Strong Buy
- Analyst Count
- EDIT 12
- CATX 11
- Target Price
- EDIT $5.40
- CATX $12.90
- AVG Volume (30 Days)
- EDIT 1.7M
- CATX 629.6K
- Earning Date
- EDIT 08-12-2025
- CATX 08-13-2025
- Dividend Yield
- EDIT N/A
- CATX N/A
- EPS Growth
- EDIT N/A
- CATX N/A
- EPS
- EDIT N/A
- CATX N/A
- Revenue
- EDIT $38,901,000.00
- CATX $1,235,000.00
- Revenue This Year
- EDIT N/A
- CATX N/A
- Revenue Next Year
- EDIT N/A
- CATX N/A
- P/E Ratio
- EDIT N/A
- CATX N/A
- Revenue Growth
- EDIT N/A
- CATX N/A
- 52 Week Low
- EDIT $0.91
- CATX $1.60
- 52 Week High
- EDIT $4.12
- CATX $16.31
- Technical
- Relative Strength Index (RSI)
- EDIT 46.57
- CATX 43.79
- Support Level
- EDIT $2.66
- CATX $3.36
- Resistance Level
- EDIT $2.78
- CATX $3.68
- Average True Range (ATR)
- EDIT 0.22
- CATX 0.25
- MACD
- EDIT -0.02
- CATX -0.03
- Stochastic Oscillator
- EDIT 39.39
- CATX 20.00
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.